Meeting
2023 ASCO Annual Meeting
Using patient-reported outcomes to assess the impact of germline genetic testing on prostate cancer patients.
Authors
Sarah M. Nielsen
Invitae, San Francisco, CA
Sarah M. Nielsen , Neal D. Shore , Mukaram Gazi , Christopher Michael Pieczonka , Sean Heron , David J Cahn , Laurence Belkoff , Aaron D. Berger , Brian Mazzarella , Joseph Veys , David Morris , Richard Bevan-Thomas , Alexander Engelman , Paul Dato , Robert Cornell , David R Wise , Mary Kay Hardwick , Brandie Heald , Robert Luke Nussbaum , Edward D. Esplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10607)
DOI
10.1200/JCO.2023.41.16_suppl.10607
Abstract #
10607
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient-reported outcomes of fully adaptive MR-guided stereotactic radiotherapy to prostate: Real-world experience from the UK.
First Author: Prantik Das
Poster
2023 ASCO Annual Meeting
Geographical impact on prostate cancer genetic testing eligibility: A preliminary study from an academic cancer center.
First Author: Samantha Beck
Poster
2022 ASCO Quality Care Symposium
Evaluation of a virtual, nurse practitioner–led, pre-counselling seminar for mainstream germline genetic testing using a patient-reported outcomes measure (PROM).
First Author: Jennifer Marie Rauw
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of pretest video genetic education in prostate cancer patients: Do patients need us?
First Author: Samantha Greenberg